Difficulty: Medium
Average Score: 83%
Practice
Which of the following is a first-line treatment for systemic lupus erythematosus?
Correct answer
D
Rationale
In the management of systemic lupus erythematosus (SLE), hydroxychloroquine is considered a first-line treatment due to its efficacy and relatively low risk profile. Hydroxychloroquine is a disease-modifying anti-rheumatic drug (DMARD) that helps control disease activity by reducing inflammation, preventing flares, and protecting against organ damage.
Corticosteroids (Option A) are often used to manage acute flares and severe symptoms in SLE but are not typically considered a first-line treatment due to their long-term side effects and the goal of minimizing their use.
Mycophenolate mofetil (Option B) and azathioprine (Option C) are immunosuppressants that may be used in SLE cases that are refractory to first-line treatments or in severe organ involvement cases. They are not usually the initial choices due to their potential side effects and the desire to start with less aggressive therapies if possible.
Educationally, understanding the rationale behind the choice of hydroxychloroquine as a first-line treatment in SLE is crucial for nurses specializing in pediatric care. It emphasizes the importance of early intervention with appropriate medications to control disease activity and prevent long-term complications in pediatric patients with SLE. Nurses need to be aware of the different treatment options available, their mechanisms of action, and potential side effects to provide comprehensive care to pediatric patients with SLE.
Corticosteroids (Option A) are often used to manage acute flares and severe symptoms in SLE but are not typically considered a first-line treatment due to their long-term side effects and the goal of minimizing their use.
Mycophenolate mofetil (Option B) and azathioprine (Option C) are immunosuppressants that may be used in SLE cases that are refractory to first-line treatments or in severe organ involvement cases. They are not usually the initial choices due to their potential side effects and the desire to start with less aggressive therapies if possible.
Educationally, understanding the rationale behind the choice of hydroxychloroquine as a first-line treatment in SLE is crucial for nurses specializing in pediatric care. It emphasizes the importance of early intervention with appropriate medications to control disease activity and prevent long-term complications in pediatric patients with SLE. Nurses need to be aware of the different treatment options available, their mechanisms of action, and potential side effects to provide comprehensive care to pediatric patients with SLE.